EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2025 Annual Results at a glance

2026.03.23

Essex Bio-Technology Reports Robust Results for FY2025. Turnover Soars 8.6% to HK$1814 million. Net Profit up 3.5% to HK$ 318.1 million. Total Dividend Increases by 16.7% to HK14 Cents per Share. Multiple Regulatory Approvals and Strategic Collaborations Strengthened Market Position.

2026.03.23

Date

Title

2023-02-10

First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases

2022-10-13

Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech

2022-08-24

Essex Bio-Technology (1061.HK) 2022 Interim Results at a Glance

2022-08-23

Essex Bio-Technology Announces 2022 Interim Financial Results

2022-08-15

Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022”

2022-07-15

EssexBio awarded “2021 China Pharmaceutical Industry Top 100 Series List” and “2022 China Pharmaceutical Brands List”

2022-05-07

Essex Bio-Technology attends the 2022 GRC-FGF Conference, with two cutting-edge scientific research accepted by GRC

2022-04-29

Essex Bio-Technology Announces Upcoming Presentation at ARVO 2022 Annual Meeting

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT